[1]刘浩.中药改善肺癌靶向治疗表皮生长因子受体酪氨酸激酶抑制剂获得性耐药研究进展[J].中国中医药信息杂志,2016,23(3):126-129.[doi:10.3969/j.issn.1005-5304.2016.03.038]
 LIU Hao.Research Progress in Ameliorating EGFR-TKIs Acquired Resistance of Targeted Therapy in Lung Cancer by Traditional Chinese Medicine[J].zhongguo zhongyiyao xinxi zazhi,2016,23(3):126-129.[doi:10.3969/j.issn.1005-5304.2016.03.038]
点击复制

中药改善肺癌靶向治疗表皮生长因子受体酪氨酸激酶抑制剂获得性耐药研究进展

参考文献/References:

[1] JIANG Z, LI C, LI F, et al. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab:a systematic review and meta analysis[J]. PLoS One, 2013,8(2):e56205.

[2] SORIA J C, MOK T S, CAPPUZZO F, et al. EGFR-mutated oncogene- addicted non-small cell lung cancer: current trends and future prospects[J]. Cancer Treatment Reviews,2012,38(5):416-430.

[3] MAEMONDO M, INOUE A, KOBAYASHI K, et al. Gefitinib or chemotherapy for Non-Small-Cell lung cancer with mutated EGFR[J]. New England Journal of Medicine,2010,362(25) :2380-2388.

[4] ROSELL R, CARCERENY E, GERVAIS R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial[J]. The Lancet Oncology,2012,13(3):239-246.

[5] 柴小姝,吴万垠,李柳宁,等.扶正抗癌方联合吉非替尼治疗PS≤2分晚期NSCLC的疗效与安全性研究[J].现代中西医结合杂志,2014,23(3):229-231,250.

[6] 刘浩,侯炜,王辉,等.参一胶囊联合吉非替尼治疗晚期非小细胞肺癌50例临床研究[J].中医杂志,2012,53(11):933-935,966.

[7] 孙建立,刘嘉湘.中医辨证结合吉非替尼治疗晚期非小细胞肺癌临床疗效及证候变化分析[J].四川中医,2009,27(11):64-66.

[8] 欧阳学农,房文铮,吴淡森,等.大黄素逆转非小细胞肺癌EGFR-TKI耐药的机制研究[J].临床肿瘤学杂志,2014,19(11):967-971.

[9] 康小红,龚亚斌,王立芳,等.蟾毒灵逆转肺腺癌H1975细胞对吉非替尼耐药的体内实验研究[J].肿瘤,2013,33(4):304-308.

[10] 李萍萍,韩淑燕.中药改善非小细胞肺癌耐药的实验和临床研究进展[M]//秦叔逵.中国临床肿瘤学进展.北京:人民卫生出版社,2010:405-407.

[11] 葛淑瑜,陈建,张家建,等.消癌平逆转厄洛替尼非小细胞肺癌耐药的作用机制研究[J].浙江中医杂志,2014,49(7):532-534.

[12] 盛琦,陈建,李菌.姜黄素逆转非小细胞肺癌吉非替尼耐药的研究[J].中国现代应用药学,2013,30(4):360-364.

[13] 郜飞宇,张爱琴,孙燕.榄香烯对肺腺癌PC9/ZD细胞株吉非替尼耐药的逆转作用[J].中华中医药学刊,2014,32(1):131-133,230.

[14] LIU J X, SHI Z M, LI H G, et al. Clinical observation on 271 cases of non small cell lung cancer treated with Yifei Kangliu Yin[J]. Chinese Journal of Integrated Traditional and Western Medicine,2001,7(4):247-250.

[15] 孙玺媛,姜梅,张伟,等.金复康口服液对非小细胞人肺腺癌吉非替尼获得性耐药的调节[J].中药材,2014,37(7):1255-1259.

[16] 陈世敏,龙顺钦,邓宏,等.扶正抗癌方对吉非替尼作用于A549人肺癌细胞的增敏作用与机制[C]//中国医师协会中西医结合医师分会.中国医师协会中西医结合医师大会第三次会议论文集.福州,2012.

[17] 肖烈钢,何本夫,朱成全.加味四君固本汤与Iressa联合抑制肺癌细胞增殖的实验研究[J].中国中医药信息杂志,2012,19(6):43-45.

[18] KOBAYASHI S, BOGGON T J, DAYARAM T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J]. New England Journal of Medicine,2005,352(8):786-792.

[19] PAO W, MILLER V A, POLITI K A, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS Medicine, 2005,2(3):225-235.

[20] SATTLER M, REDDY M M, HASINA R, et al. The role of the c-Met pathway in lung cancer and the potential for targeted therapy[J]. Therapeutic Advances in Medical Oncology,2011,3(4):171-184.

[21] TURKE A B, ZEJNULLAHU K, WU Y L, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC[J]. Cancer Cell,2010,17(1):77-88.

[22] 熊杏安,王梦,蔡志强.表皮生长因子受体-酪氨酸激酶抑制剂的耐药机制[J].国际肿瘤学杂志,2014,41(7):515-517.

[23] 肖海娟,许建华,孙珏,等.中医药逆转肿瘤多药耐药机制研究进展[J].中国中医药信息杂志,2012,19(6):108-110.


?

备注/Memo

基金项目:国家自然科学基金(81573950);北京市自然科学基金(7122151)

更新日期/Last Update:

2016-02-22